Results of ALLEVIATE 1 and ALLEVIATE 2 Phase 3 trials of cebranopadol, a first-in-class, dual NOP/MOP receptor agonist for the treatment of acute pain after abdominoplasty and bunionectomy (ASRA-SPRING 2026) - Apr 18, 2026 - Abstract #2318384; Pres time: Apr 17, 2026; 04:30 PM - 06:00 PM; "In both trials, rescue medication use was significantly lower than with placebo. •These trials represent two registrational, Phase 3 studies highlighting cebranopadol's potential to become a valuable new therapy for acute pain management."
P3 data • Addiction (Opioid and Alcohol) • Aesthetic Medicine • CNS Disorders • Depression • Pain • Pruritus
|
|
Todd Bertoch; Megan Shram; James Hackworth; Joseph Grieco; Harold Minkowitz
|